Ting Lu

Dr. Ting Lu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2021 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
SLShan Liu
Shan Liu
JYJianyu Yang
Jianyu Yang
GSGuohuan Sun
Guohuan Sun
YZYawen Zhang
Yawen Zhang
CCCong Cheng
Cong Cheng
TLTing Lu
Ting Lu
RUNX1 is a Runt family transcription factor that plays a critical role in normal hematopoiesis, including the differentiation and proliferation of hematopoietic cells. RUNX1 mutations, including chromosomal translocations, cause abnormal cell differentiation, but the mutation alone is not sufficient to cause leukemia. In MLL-fusion-induced leukemia, dysregulated wild-type RUNX1 can promote leukemia survival. Nevertheless, the underlying mechanisms of dysregulated wild-type RUNX1 in leukemia development have not been fully elucidated. This study overexpressed and knocked down RUNX1 expression in THP-1 human leukemia cells and CD34+ hematopoietic stem/progenitor cells to investigate the biological functions affected by dysregulated RUNX1. Our data indicated RUNX1 facilitated proliferation to promote leukemia cell growth. Furthermore, we demonstrated that RUNX1 knockdown in leukemia cells drastically diminished colony-forming ability. Finally, the RUNX1-knocked down cell depletion phenotype could be rescued by overexpression of CENPE, a cell proliferation gene and a RUNX1 direct target gene. Our results indicate a possible mechanism involving the RUNX1-CENPE axis on promoting leukemic cell growth.

27 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LYLiu Yang
Liu Yang
HZHouyu Zhang
Houyu Zhang
XYXue Yang
Xue Yang
TLTing Lu
Ting Lu
SMShihui Ma
Shihui Ma
TCTao Cheng
Tao Cheng
Acute myeloid leukemia (AML) refers to a heterogeneous group of hematopoietic malignancies. The well-known European Leukemia Network (ELN) stratifies AML patients into three risk groups, based primarily on the detection of cytogenetic abnormalities. However, the prognosis of cytogenetically normal AML (CN-AML), which is the largest AML subset, can be hard to define. Moreover, the clinical outcomes associated with this subgroup are diverse. In this study, using transcriptome profiles collected from CN-AML patients in the BeatAML cohort, we constructed a robust prognostic Cox model named NEST (Nine-gEne SignaTure). The validity of NEST was confirmed in four external independent cohorts. Moreover, the risk score predicted by the NEST model remained an independent prognostic factor in multivariate analyses. Further analysis revealed that the NEST model was suitable for bone marrow mononuclear cell (BMMC) samples but not peripheral blood mononuclear cell (PBMC) samples, which indirectly indicated subtle differences between BMMCs and PBMCs. Our data demonstrated the robustness and accuracy of the NEST model and implied the importance of the immune dysfunction in the leukemogenesis that occurs in CN-AML, which shed new light on the further exploration of molecular mechanisms and treatment guidance for CN-AML.

1 February 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
SLShan Liu
Shan Liu
JYJianyu Yang
Jianyu Yang
GSGuohuan Sun
Guohuan Sun
YZYawen Zhang
Yawen Zhang
CCCong Cheng
Cong Cheng
TLTing Lu
Ting Lu
Corrigendum: RUNX1 Upregulates CENPE to Promote Leukemic Cell Proliferation